



## **DCprime and Glycotope announce licensing agreement and collaboration**

**Leiden, The Netherlands, and Berlin, Germany, 18 July 2018** – DCprime BV, a clinical stage biotechnology company focused on cell-based cancer vaccines, and Glycotope GmbH, a clinical stage immuno-oncology company built on world-leading glycobiology expertise, announce today that they have entered into a license agreement and research collaboration.

Under the agreement, DCprime has obtained the global research and commercialization rights to certain process development patents owned by Glycotope. In addition, the companies have initiated a research collaboration to evaluate novel immunotherapeutic approaches to solid tumours, based on the combination of their proprietary technologies.

Henner Kollenberg, Managing Director, Glycotope commented: “This is an exciting opportunity and we look forward to working with DCprime. Through this collaboration we will look to draw on DCprime’s expertise in the development of dendritic cell therapies and combine this with our own knowledge of glyco-biology to evaluate potential new immunotherapies.”

Erik Manting, CEO of DCprime added: “It is a pleasure to work with Glycotope based on their strong basis in process development and immuno-oncology. This collaboration allows us to pursue new and innovative combination therapies based on DCOne® and immunomodulatory antibodies.”

### **About DCprime bv**

DCprime is a privately owned, clinical stage biotechnology company focused on cancer immunotherapies. Founded in 2005, DCprime currently develops cell based cancer vaccines based on its proprietary technology platform DCOne®, with lead DCOne® asset DCP-001 being studied in patients with acute myeloid leukemia (AML). A completed Phase I study has demonstrated that DCP-001 is generally safe and capable of inducing a broad immune response. DCprime has received orphan drug designation from the European Medicines Agency for DCP-001 in AML and has commenced a multi-centre Phase II trial. DCprime intends to develop DCOne®-based vaccines in other cancer indications, including multiple myeloma and solid tumours. For more information, visit [www.dcpriime.com](http://www.dcpriime.com).

### **About Glycotope GmbH**

Glycotope is a clinical-stage immuno-oncology company built on world-leading glyco-biology expertise. The company draws on its long heritage in glyco-biology to create highly specific mAbs targeting glyco-epitopes, and glyco-optimized mAbs with enhanced performance. Glycotope has a growing pipeline of high-value cancer therapies focused around the glyco-optimized antibody gatipotuzumab which targets the novel glyco-epitope target TA-MUC1. Its lead clinical program is in Phase I/II in combination with tomuzotuximab, a glyco-optimized second-generation anti-EGFR. Glycotope has entered into a partnership with Daiichi Sankyo for antibody drug conjugates (ADCs) and is also exploring multiple additional formats based on gatipotuzumab.

## **Contact**

### **DCprime:**

Erik Manting  
DCprime bv  
e.manting@dcprime.com  
+31629006169

### **Glycotope:**

Henner Kollenberg  
Glycotope GmbH  
contact@glycotope.com  
+49 30 9489 2600

### **Consilium Strategic Communications**

Chris Gardner, Jonathan Birt, Jessica Hodgson and Hendrik Thys  
Phone: +44 (0) 20 3709 5700  
Email: [glycotope@consilium-comms.com](mailto:glycotope@consilium-comms.com)